Day 1: Building a Diversity Focused Strategy to Execute Real Change
Opening Remarks
Opening Remarks
JUNE 24TH  |  12:00 PM - 12:30 PM EST


Learning from Past Mistakes and Charting a New Path Forward

JUNE 24TH  |  12:30 PM - 1:50 PM EST

Community leaders and medical professionals that represent and understand underserved communities will discuss lessons learned from past mistakes in clinical research and the path forward for creating a more equitable clinical development process. 

Moderator: Dr. Michelle McMurry-Heath, MD, PhD, CEO, BIO
  • Dr. Elena V. Rios, MD, MSPH, FACP, President & CEO, National Hispanic Medical Association, & President, National Hispanic Health Foundation 
  • Dr. Randall C. Morgan, Jr., MD, MBA, President & CEO, W. Montague Cobb/NMA Health Institute
  • Silas Buchanan, CEO, Institute for eHealth Equity
  • Tom Anderson, MPH, Executive Director, Association of American Indian Physicians (AAIP)


The Social and Business Imperative of Increasing Clinical Trial Diversity

JUNE 24TH  |  2:00 PM - 3:20 PM EST

Biopharmaceutical CEOs and industry leaders will discuss the social and business imperative of diverse participation in clinical trials and the best way to achieve it by sharing insights from the pandemic.

Moderator: Dr. Cartier Esham, PhD, Chief Scientific Officer, BIO
  • Dr. Julie Gerberding, MD, MPH, Chief Patient Officer, Executive VP of Population Health, Global Policy, and Strategic Communications, Merck
  • Staci Hargraves, VP, Portfolio Management, Janssen (Johnson & Johnson)
  • Dr. Ted W. Love, MD, CEO, Global Blood Therapeutics
Setting Targets
Change Comes from Within: Setting Targets and Building an Organization Focused on Health Equity

JUNE 24TH  |  3:30 PM – 4:50 PM EST

Hear from executives and clinical development leaders that have set targets and enacted internal changes to increase clinical trial diversity. 

Moderator: Dr. Barbara Bierer, MD, Director, Multi-Regional Clinical Trials Center
  • Dr. Asha S. Collins, PhD, US Clinical Operations Head, Genentech 
  • Dr. Darryl Sleep, MD (MBBCh, FCS(SA)), Chief Medical Officer, Amgen 
  • Dr. Lisa Dunkle, MD, VP of Clinical Development, Global Medical Lead for COVID-19 Vaccine, Novavax  
  • Dr. Melanie Ivarsson, PhD, MBA, Chief Development Officer, Moderna
  • Tamar Thompson, MPH, VP, US Government Affairs & Policy, Alexion Pharmaceuticals

Day 1 Networking Session

Engage in an interactive discussion with your peers within the community, academia, and private sector on how to build a diversity focused strategy.  Particularly, how to create a more equitable clinical development process, critical ways biopharmaceutical companies can include a diverse patient population in clinical trial and what can companies do to initiate internal changes to increase clinical trial diversity.

Day 2: Approaches to Implementing a Diversity Focused Strategy to Execute Real Change
Opening Remarks
Opening Remarks
JUNE 25TH  |  12:00 PM - 12:30 PM EST

Dr. Cartier Esham, PhD, Chief Scientific Officer of BIO

Taking Lessons Learned from COVID to Advance More Inclusive Approaches to Clinical Trials

JUNE 25TH  |  12:30 PM – 1:50 PM EST

Industry leaders and researchers will discuss real world examples of trial design tools that enabled more inclusivity in trials during the pandemic and the implications for their continued use.

Moderator: Esther Krofah, MPP, Executive Director, Faster Cures, A Center of the Milken Institute 
  • Dr. Merdad Parsey, MD, PhD, Chief Medical Officer, Gilead  
  • Dr. Janelle Sabo, PharmD, VP of Clinical Capabilities: Clinical Design, Delivery & Analytics (CDDA), Eli Lilly 
  • John L. Newby II, JD, CEO, Virginia Biotechnology Association
  • Dr. Stacey J. Adam, PhD, Associate VP of Research Partnerships, Foundation for the National Institutes of Health (FNIH)
Data  & Tech
The Role of Technology and Data in Building a Sustainable, Expanded and Inclusive Clinical Trial…

JUNE 25TH  |  2:00 PM – 3:20 PM EST

Accessible technologies are critical to creating an inclusive clinical trial network. Experts will provide an overview of what trial designs, data and tools can enable diverse patient participation.

Moderator: Dr. Cartier Esham, PhD, Chief Scientific Officer, BIO 
  • Carolyn Magill, MBA, CEO & Board Director, Aetion  
  • Dr. Cynthia Verst, PhD, President, R&DS Design & Delivery Innovation,  IQVIA 
  • David Coman, MBA, CEO, Science 37
  • Matt Walz, MBA, CEO, Trialbee
  • Maulik Mehta, MBA, Chief Business Officer, TriNetX


The Imperative of Community & Patient Engagement: Building Trust in and Awareness of Opportunities…

JUNE 25TH  |  3:30 PM – 4:50 PM EST

Engaging with patients and community advocates is critical to advancing education about and awareness of opportunities to participate in clinical trials.  Hear from leading advocates and thought leaders about how build, support and engage community engagement networks. 

Moderator: Donna R. Cryer, JD, President & CEO of the Global Liver Institute 
  • Debra Fraser-Howze, Principle, D. Fraser Associates, Founder, Choose Healthy Life
  • Dr. James Powell, MD, Principal Investigator, National Medical Association, Project IMPACT
  • Kim Cantor, MPA, Senior Director, Pyxis Partners, NIH All of Us Community and Provider Partner Network
  • Maya Bermingham, JD, Senior VP, Public Policy and Government Affairs, Regeneron
  • Dr. Stephaun Wallace, PhD, Director of External Relations, HIV Vaccine Trials Network

Day 2: Networking Session

Connect with industry leaders and researchers on actionable approaches to implement a diversity focused strategy.  Discuss practical examples that can be utilized as design and data tools to enable clinical trial diversity.  Brainstorm ideas on how to advance awareness and increase knowledge opportunities for patients to engage in clinical trials, and infrastructure needed to build and support community engagement networks to ensure patient diversity.